Compare CDMOs with oral solid dose manufacturing capabilities for tablets, capsules, and modified-release products. Filter by batch size, coating technology, and regulatory approvals.
364 companies listed
Tablets and capsules are the workhorse of pharma, roughly 60% of all drug products, so "oral solid dose CDMO" returns a crowded field. The differences that matter are technical, not marketing. Your API's flow and compressibility decide the granulation route: direct compression if it behaves, wet or dry granulation if it doesn't. A shop built for high-shear wet granulation isn't automatically the right home for a moisture-sensitive compound that needs roller compaction. Then there's scale. A CDMO that runs elegant 5,000-tablet clinical batches may not hold content uniformity at two million tablets a day. Heading toward extended- or delayed-release? Confirm the coating and multiparticulate expertise before you commit. Potent compound? Check the containment band (OEB) of the suite you'd actually run in. 364 CDMOs here list oral solid dose. Filter by batch size, coating technology, and regulatory market.
Oral solid dose (OSD) manufacturing is the highest-volume pharmaceutical manufacturing segment. Tablets and capsules account for approximately 60% of all drug products. The manufacturing process includes blending, granulation (wet or dry), compression or encapsulation, coating, and packaging. CDMOs range from small clinical-batch specialists to high-volume commercial manufacturers producing millions of units per day.
Modified-release technologies differentiate premium OSD CDMOs. Extended-release, delayed-release, and pulsatile-release formulations require specialized equipment and expertise in polymer coating, matrix systems, osmotic delivery, and multiparticulate approaches (pellets in capsules). These formulations improve patient compliance and can extend product lifecycle.
France
Pierre Fabre CDMO is the contract development and manufacturing arm of the Pierre Fabre Group, a French pharmaceutical and dermo-cosmetics company. Offers over 20 years of CDMO services across pharma and non-pharma active ingredients, dry forms, non-sterile liquids, and biologics including monoclonal antibodies and ADCs. Operates R&D site in Toulouse and 3+ industrial sites in France. Expertise spans extraction, chromatographic purification, chemical synthesis, cytotoxic compound production, plant cell culture, and supercritical CO2 technology. Manufactures 2,100 metric tons of plant extracts and 100+ active ingredients annually.
Canada
Pillar5 Pharma is a Canadian CDMO founded in 2009, specializing in sterile ophthalmic manufacturing and solid dose production. Market leader in Multi-Dose Preservative Free (MDPF) technology in North America. Produces 30 million ophthalmic bottles and 255 million solid dose tablets per year with 210+ employees. Acquired by ANJAC Sante & Beaute and is also a Prestige Consumer Healthcare company. Health Canada approved, holds FDA Drug Establishment Registration. Acquired former Pfizer site in Arnprior, Ontario.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.